Loading
Every dated change on the records linked to Recurrent and metastatic nasopharyngeal carcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Recurrent/metastatic nasopharyngeal carcinoma, first line with chemotherapy and later lines
A milestone in how this cancer is treated.
Gemcitabine, taxane or capecitabine-based chemotherapy; nivolumab or pembrolizumab if no prior PD-1 antibody; trials of antibody-drug conjugates (MRG003, BL-B01D1, YL201) and EBV-specific T cells.
Gemcitabine and cisplatin with a PD-1 antibody (toripalimab, JUPITER-02; camrelizumab, CAPTAIN-1st; tislelizumab; penpulimab), then PD-1 maintenance; locoregional radiotherapy to the primary in patients with a good response.
Stereotactic radiotherapy or resection of limited metastases with systemic therapy.
Endoscopic nasopharyngectomy (better survival and fewer complications than re-irradiation in a randomised trial); neck dissection for nodal recurrence.
Hyperfractionated intensity-modulated re-irradiation or proton therapy with careful dose constraints; systemic therapy where re-irradiation is unsafe.
Median progression-free survival 9.
PFS HR 0.
A milestone in how this cancer is treated.